La vendita allo scoperto per TriSalus Life Sciences dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di TriSalus Life Sciences. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

TriSalus Life Sciences (NASDAQ:TLSI) Azioni, Report sulle vendite allo scoperto

TriSalus Life Sciences

TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences Inc

Shares of MasTec Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) continued their upward trajectory in early trading on Tuesday, after climbing last week on <a href="https://www.benzinga.com/news/24/11/41688665/amazon-posts-upbeat-results-joins-cardinal-health-waters-atlassian-charter-communications-mastec-and">the company's raised 2024 adjusted earnings guidance</a>.
Despite the recent rally, the stock has more runway. The Coral Gables, Florida-based company's Power Delivery, Clean Energy &amp; Infrastructure (CE&amp;I), and Communications segments are "turning the corner," according to Truist Securities.
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58ac4af1b85e930001e6383a/jamie-cook">Analyst Jamie Cook</a> upgraded the rating for MasTec from Hold to Buy, while raising the price target from $133 to $173.
The MasTec Thesis: The company's Power Delivery, CE&amp;I, and Communications segments are poised for revenue growth and margin expansion, Cook said in the upgrade note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
MasTec is "solidifying its positioning in utility transmission and distribution through the Henkels &amp; McCoy acquisition and in renewables through the IEA acquisition," the analyst stated. 
The company and rival Quanta Services Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) are both "well positioned to lead the market and grow given competitive advantages which include scale, workforce, and balance sheet," he added.
"We expect strong top line growth and margin expansion in 2025 tied to secular growth in renewables, significant funding for communications infrastructure associated with BEAD funding and MTZ's recently expanded relationship with AT&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>), and new major project wins including the $1.5 billion high-voltage transmission project MTZ announced last quarter," Cook wrote. After facing two years of margin pressure, MasTec seems poised for margin expansion in 2025 and "has line of sight to reaching double-digit EBITDA margins over the medium term," he further said.
Price Action: Shares of MasTechad risen by 3.22% to $136.87 at the time of publication on Tuesday.
Read More: <a href="https://www.benzinga.com/news/earnings/24/09/40859294/mastec-stock-rallies-31-in-the-past-6-months-is-mtz-a-buy-right-now">MasTec Stock Rallies 31% in the Past 6 Months: Is MTZ a Buy Right Now?</a>

Analyst Color

Long Ideas

Upgrades

Price Target

Analyst Ratings

Movers

Trading Ideas

Infrastructure Construction Company MasTec Is Poised For Double Digit Margin Expansion, Analyst Says

WIIM

BOWL

Bowlero Corp shares are trading higher. JP Morgan maintained an Overweight rating on the stock.

Piper Sandler analyst Korinne Wolfmeyer reiterates Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) with a Neutral and raises the price target from $18 to $21.

News

Reiteration

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Piper Sandler Reiterates Neutral on Hims & Hers Health, Raises Price Target to $21

HCKT

Hackett Group shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 adjusted EPS guidance above estimates. Also, Craig-Hallum raised its price target on the stock from $30 to $32.

In the current session, the stock is trading at $3.81, after a 3.81% increase. Over the past month, LexinFintech Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) stock increased by 14.15%, and in the past year, by 80.20%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1730824264_0.png" alt="Past Year Chart" />

<h3>LexinFintech Holdings P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 24.2 in the Consumer Finance industry, LexinFintech Holdings Inc. has a lower P/E ratio of 5.3. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1730824264_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

A Look Into LexinFintech Holdings Inc's Price Over Earnings

Piper Sandler analyst Thomas Champion reiterates Vimeo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMEO#NASDAQ">VMEO</a>) with a Neutral and raises the price target from $5 to $7.

VMEO

Piper Sandler Reiterates Neutral on Vimeo, Raises Price Target to $7

NRG Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) has outperformed the market over the past 5 years by 5.24% on an annualized basis producing an average annual return of 18.49%. Currently, NRG Energy has a market capitalization of $17.75 billion. 
Buying $100 In NRG: If an investor had bought $100 of NRG stock 5 years ago, it would be worth $234.21 today based on a price of $86.00 for NRG at the time of writing.
<h3>NRG Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730824226_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today

Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) has outperformed the market over the past 5 years by 16.86% on an annualized basis producing an average annual return of 30.12%. Currently, Datadog has a market capitalization of $42.19 billion. 
Buying $1000 In DDOG: If an investor had bought $1000 of DDOG stock 5 years ago, it would be worth $3,814.23 today based on a price of $125.14 for DDOG at the time of writing.
<h3>Datadog's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730824221_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DDOG

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,800 Today

Clearwater Paper shares are trading higher. RBC Capital reiterated an Outperform rating on the stock.

ICHR

Ichor Holdings shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 revenue guidance above estimates. Also. B. Riley Securities raised its price target on the stock from $36 to $38.

INGR

Ingredion shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results and raised its FY24 adjusted EPS guidance above estimates.

Piper Sandler analyst Adam Maeder reiterates Inspire Medical Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>) with a Overweight and raises the price target from $255 to $260.

INSP

Piper Sandler Reiterates Overweight on Inspire Medical Systems, Raises Price Target to $260

RBC Capital analyst Conor McNamara maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a Sector Perform and raises the price target from $86 to $89.

HOLX

RBC Capital Maintains Sector Perform on Hologic, Raises Price Target to $89

AOSL

Alpha & Omega shares are trading lower after the company reported worse-than-expected Q1 adjusted EPS results. B. Riley Securities lowered its price target on the stock from $50 to $47.

Mark Cuban is an outspoken billionaire and part-owner of the Dallas Mavericks but also one of the most vocal critics of the former president. He has used terms like &#8220;fascist&#8221; to describe Trump&#8217;s behavior. However, Cuban was recently seen on ABC justifying his business relationship with Miriam Adelson, who gave Trump an astounding $100 million to support his 2024 election campaign.
Don't Miss:
<ul>
<li>With over 7.8K investors including Meta, Google, And Amazon Execs — this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai">Be an early investor with just $1,000 for only $0.50/share today.</a></li>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
</ul>
Adelson&#8217;s hefty donation to Trump – the largest of any sports team owner – shows she's all-in on Trump's campaign. That has made things somewhat awkward for Cuban, considering his loud and clear support for Kamala Harris, who is running against Trump.
Yet, when asked how he felt about this partnership, Cuban brushed off the issue. &#8220;Do you know how everyone is voting who you work with? Do you know how the owners of your company are voting? This is America. People get to choose their candidates and vote for who they want, which makes it amazing,&#8221; Cuban said in an interview. Cuban&#8217;s message is that differing political views shouldn't interfere with running a business.
See Also: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"> You can still get 4,000 of its pre-IPO shares for just $1,000</a>
Cuban also pointed out that he's not giving money to Harris – or any other political candidate, for that matter. Despite his <a href="https://www.benzinga.com/news/24/09/40745014/kamala-harris-is-pro-business-mark-cuban-says-vice-presidents-centre-100-policies-differ-from-bidens">vocal support for the current vice president</a>, Cuban hasn&#8217;t donated a penny to her campaign. He believes in making a difference through his words and influence instead of writing checks.
He's been on social media defending Harris and has engaged in fiery debates, <a href="https://www.benzinga.com/markets/equities/24/10/41568486/mark-cuban-highlights-trumps-potential-to-ruin-christmas-but-he-might-also-end-up-spoiling-the-p">calling out Trump's behavior</a> as dangerous and out of touch. Cuban also stated in the same ABC interview that &#8220;Donald Trump is not a normal candidate,&#8221; claiming that he has used divisive language and taken actions that, in Cuban&#8217;s opinion, verge on authoritarianism.
Trending: If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?
Despite clashing ideologies, Cuban seems comfortable keeping his business relationships and political beliefs separate. Miriam Adelson, who inherited a vast fortune from her late husband Sheldon Adelson, now <a href="https://www.benzinga.com/news/23/12/36231225/mark-cuban-to-retain-25-stake-in-dallas-mavericks-after-sale-to-adelson-family-report">shares ownership of the Mavericks with Cuban</a>. The Adelson family is deeply involved in politics and their support of Trump hasn't wavered. On the other hand, Cuban is sticking to his guns – supporting Harris in the media and making the case for what he believes is best for the country.
At the end of the day, Cuban seems determined to stay true to his political convictions and his business partnerships. &#8220;This is America,&#8221; he says – a place where people can disagree, even sharply and still find ways to work together.
Read Next:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
</ul>

Startups

'This Is America,' Mark Cuban Says, Justifying His Business Relationship With Trump's $100M Megadonor And Mavericks Co-Owner

<a href="https://www.benzinga.com/personal-finance/24/09/40714364/survive-anything-kevin-oleary-claims-you-need-5-million-in-savings-heres-how-you-can-reach-that-">Kevin O'Leary</a>, best known from Shark Tank, has backed Elon Musk's sweeping $2 trillion plan to slash federal spending. With former President Donald Trump's backing, Musk is proposed to head the Department of Government Efficiency (DOGE) if Trump secures a second term.&nbsp;
Don't Miss:
<ul>
<li>With over 7.8K investors including Meta, Google, And Amazon Execs — this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai">Be an early investor with just $1,000 for only $0.50/share today.</a></li>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
</ul>
O'Leary enthusiastically remarked on Fox News, "Release the hounds" about unleashing Musk's cost-cutting skills across federal agencies. "Let them in there and come back with a shopping list of ideas and let's debate it. Why not? We need to find some savings."
In O'Leary's view, the U.S. federal government is "the biggest business in America." He sees Musk, the mind behind Tesla and SpaceX, as uniquely equipped to tackle this budget behemoth.&nbsp;
"Who has the executional skills and the track record to even look at this problem?" he said, emphasizing that Musk's focus and determination make him an ideal candidate. Indeed, O'Leary believes that Musk's efficiency ethos, which has driven companies like SpaceX to success, would transfer seamlessly to federal budget cuts – an area few entrepreneurs would tread.
Trending: The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a>
Musk has clarified that he views today's government spending as unsustainable, especially with national debt interest payments now outstripping the defense budget.&nbsp;
Speaking at a Trump rally, he linked federal spending to inflation and increased taxes, which he warned are squeezing <a href="https://www.benzinga.com/personal-finance/24/08/40582239/californias-new-plan-taxpayers-might-soon-be-funding-home-loans-for-illegal-migrants-heres-what-">taxpayers </a>dry. With his proposal to shave off $2 trillion, Musk aims to start the work he sees as vital for long-term economic stability.
But this grand vision has detractors. Some experts question whether cutting a third of federal spending is possible without compromising essential services.&nbsp;
Analysis from the Washington Post noted that Musk&#8217;s cuts could gut programs like health care, food security and housing, impacting millions of Americans. Even previously untouchable sectors, such as Social Security and the military, may be affected.&nbsp;
See Also: Over the last five years, the price of gold has increased by approximately 83% — Investors like Bill O&#8217;Reilly and Rudy Giuliani are using this platform to <a href="https://www.benzinga.com/money/american-hartford-gold">create customized gold IRAs to help shield their savings from inflation and economic turbulence.&nbsp;</a>
Musk acknowledged on X (formerly Twitter) that his proposed cuts could result in economic turmoil, suggesting that hard times would be ahead before any benefits emerged.
Still, O'Leary remains undeterred. He sees Musk's focus as an asset, contrasting the entrepreneur's "100% signal" approach with what he describes as other business leaders' focus on "noise." To O'Leary, Musk's dedication to his projects means he is all about the mission and not distracted by side issues, making him ideal for leading such a challenging initiative.&nbsp;
He even suggested that Musk go beyond the $2 trillion target. "We've got to go find $2 trillion; we've got to go find $5 trillion," O'Leary urged.
Read Next:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"> You can still get 4,000 of its pre-IPO shares for just $1,000</a></li>
</ul>

Kevin O'Leary Supports Elon Musk's $2 Trillion Plan To Slash Government Spending With Trump's Backing–'It's Time To Release The Hounds'

COGT

Cogent Biosciences shares are trading lower after the company announced Bezuclantinib presentations at the 66th annual American Society of Hematology meeting.

RBC Capital analyst Sean Dodge reiterates IQVIA Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) with a Outperform and maintains $270 price target.

RBC Capital Reiterates Outperform on IQVIA Hldgs, Maintains $270 Price Target

Keefe, Bruyette &amp; Woods analyst Meyer Shields maintains Willis Towers Watson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTW#NASDAQ">WTW</a>) with a Outperform and raises the price target from $352 to $359.

Keefe, Bruyette & Woods Maintains Outperform on Willis Towers Watson, Raises Price Target to $359

PRAA

PRA Group shares are trading higher after the company reported better-than-expected Q3 financial results. Additionally, Truist Securities maintained a Buy rating on the stock and raised its price target from $28 to $31.

In a report released yesterday, William Plovanic from Canaccord Genuity maintained a Buy rating on TriSalus Life Sciences (TLSI – Research Report),...

TriSalus Life Sciences: Strong Buy on Warrant Exchange Success and Anticipated Technical Rebound

TriSalus Life Sciences (TLSI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst William P...

TriSalus Life Sciences: A Comprehensive Analysis of Commercial Success and Promising Drug Pipeline Prospects

TriSalus Life Sciences GAAP EPS of -$0.21, revenue of $7.4M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
TriSalus Life Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/tlsi-stock-quote/">TLSI</a>) just reported results for the second quarter of 2024.<ul><li>TriSalus Life Sciences reported earnings per share of -21 cents. This was above the analyst estimate for EPS of -49 cents.</li><li>The company reported revenue of $7.36 million.</li><li>This was 6.88% better than the analyst estimate for revenue of $6.89 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/tlsi-stock-earnings-trisalus-life-sciences-for-q2-of-2024/">TLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

TLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q2 2024

TriSalus Life Sciences, Inc. (TLSI) Q2 2024 Earnings Call Transcript

Buy Rating Affirmed on TriSalus Life Sciences Amid Strong Financials and Strategic Growth Initiatives

JonesTrading analyst Justin Walsh has reiterated their bullish stance on TLSI stock, giving a Buy rating yesterday. Justin Walsh has given his Buy ...

TriSalus Life Sciences: Outperforming Expectations with a Buy Rating Despite Adjusted Price Target

Maxim Group analyst Jason McCarthy maintained a Buy rating on TriSalus Life Sciences (TLSI – Research Report) yesterday and set a price target of $...

TriSalus Life Sciences: A Strong Buy on Robust Revenue Growth and Promising Clinical Advancements

Northland analyst Carl Byrnes initiated coverage of TriSalus Life Sciences (TLSI) with an Outperform rating and $12.50 price target Published first...

TriSalus Life Sciences initiated with an Outperform at Northland

TriSalus Life Sciences files to sell 10.59M shares of common stock for holders

TLSI

TLSIW

Press Releases

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants

TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting

TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants

TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation

TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call

TriSalus Reports Q2 2024 Financial Results and Business Update

TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System

Comments

TriSalus Life Sciences

Vendite allo scoperto

TriSalus Life Sciences (NASDAQ:TLSI) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO